Table 2 Baseline cancer demographics
From: Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
Cases (n = 101) | Controls (n = 201) | P value | |
|---|---|---|---|
Single agent vs. combined | |||
Combination | 28 (28) | 14 (7) | < 0.001 |
Monotherapy | 73 (72) | 177 (93) | < 0.001 |
Combined ICI | |||
Ipilimumab (anti-CTLA4) + nivolumab (anti-PD1) | 24 (24) | 13 (6) | < 0.001 |
Ipilimumab (anti-CTLA4) + pembrolizumab (anti-PD1) | 1 (1) | 0 | 0.33 |
Tremelimumab (anti-CTLA4) + avelumab (anti-PD1) | 1 (1) | 0 | 0.33 |
Tremelimumab (anti-CTLA4) + durvalumab (anti-PD1) | 2 (2) | 1 (0) | 0.26 |
Monotherapy ICIa | |||
Pembrolizumab (anti-PD1) | 35 (35) | 62 (31) | 0.50 |
Nivolumab (anti-PD1) | 25 (25) | 85 (42) | 0.003 |
Ipilimumab (anti-CTLA4) | 6 (6) | 28 (14) | 0.04 |
Tremelimumab (anti-CTLA4) | 1 (1) | 0 | 0.33 |
Atezolizumab (anti-PDL1) | 6 (6) | 2 (1) | 0.02 |
Avelumab (anti-PDL1) | 0 | 0 | 1.00 |
Durvalumab (anti-PDL1) | 0 | 0 | 1.00 |
Overall types of ICI | |||
Any anti-PD1 | 85 (84) | 160 (80) | 0.34 |
Any anti-CTLA4 | 35 (35) | 42 (21) | 0.01 |
Any anti-PDL1 | 9 (9) | 3 (1) | 0.003 |
Days of follow-up [IQR] | 175 [89,363] | 290 [139,543] | < 0.001 |
Other immune side effects during treatmentb | |||
No other immune side effects | 51 (50) | 86 (43) | 0.20 |
Hypophysitis/pituitary/adrenal | 6 (6) | 14 (7) | 0.74 |
Pneumonitis | 30 (30) | 24 (12) | < 0.001 |
Hepatitis | 8 (8) | 11 (5) | 0.41 |
Colitis | 9 (9) | 27 (13) | 0.25 |
Dermatitis | 6 (6) | 5 (2) | 0.19 |
Neurological | 11 (11) | 4 (2) | 0.001 |
Gastritis | 3 (3) | 5 (2) | 1.00 |